Akari Therapeutics appoints Vatnak Vat-Ho chief business officer
Bitget2026/10/13 13:05- Akari Therapeutics named Vatnak Vat-Ho chief business officer to lead corporate strategy, partnering, licensing, investor engagement.
- Vat-Ho brings 20+ years in oncology business development, biopharma strategy, equity research, healthcare investing; worked on deals totaling $25 billion.
- Most recently served as chief business officer at Ryvu Therapeutics, where he closed an ADC payload collaboration with Exelixis.
- At Ryvu, he also originated a multi-target immuno-oncology research collaboration with BioNTech.
- Appointment comes as Akari advances TROP2-targeted ADC AKTX-101 toward the clinic, alongside its PH1 payload platform.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Report: CoreWeave’s three founders cashed out $3.3 billions before stock price crash
The three co-founders of CoreWeave have cumulatively cashed out over $3.3 billion since the company went public, while its current stock price has plummeted more than 50% from its peak. At present, the company's bonds maturing in 2032 have fallen into distressed territory, with CDS spreads surging to 1,117 basis points, implying a default probability of 63%. Market concerns about its ability to repay debt are now spreading along the financing chain of AI computing power leasing.
BRIEF-Union Pacific CFO Jennifer Hamann To Step Down
BUZZ - Citizens Financial shares fall as Q3 revenue misses expectations
Crypto prices
More
